<DOC>
	<DOC>NCT00678392</DOC>
	<brief_summary>The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.</brief_summary>
	<brief_title>Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis Evidence of measurable disease Must have failed one prior systemic firstline regimen for metastatic renal cell cancer Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Axitinib in Second Line Treatment of Patients With Metastatic Renal Cell Cancer</keyword>
</DOC>